Craig Sayers
My name is Craig Sayers, originally from Burnley, I trained at Edinburgh University graduating in 1993. I am 52 years young.
I have worked as a GP in prisons since 2000 and have been the Clinical Lead for Prison Healthcare in NHS Forth Valley since 2011.
I have been the Scottish Representative for the RCGP Secure Environments Group since 2013.
My area of interest is in relation to addictions management within the custodial setting.
I have recently been asked to be the National Lead Clinician/Professional Ambassador for National Prisoner Care Network. I am looking forward to taking up this exciting new challenge and opportunity.
In relation to this poster presentation, we are looking to continue to collate data both during our patients time in prison and following liberation with a view to journal publication in 2022.
Outcomes and resource utilisation following introduction of injectable prolonged-release buprenorphine (iPRB) in Scottish prisons
Title: Outcomes and resource utilisation following introduction of injectable prolonged-release buprenorphine (iPRB) in Scottish prisons.
Aims: As part of Covid-19 contingency planning for opioid dependence treatment (ODT), the Scottish Government provided funds to make iPRB widely available in prisons in Scotland in order to reduce the need for daily administration and ensure continuity of treatment for patients in custody. This service evaluation will provide critical insights into patient experiences and staff resource utilisation following initiation of iPRB initiation in this setting.
Design: Routinely collected clinical and demographic data were extracted from electronic records and patient reported outcomes including satisfaction and experiences of treatment were evaluated via questionnaires. Retention in treatment, including continuity of care post-liberation, is also being evaluated.
Setting: Patient characteristics, patient-reported outcomes and resource utilisation following introduction of iPRB for ODT in three prisons in Forth Valley, Scotland between May 2020 and August 2021 will be described. To date, 104 people have been treated with iPRB (72.3% male, 68% switched from methadone, 8.7% switched from sublingual buprenorphine, 23.3% new treatment initiations).
Measurements: Data collated at various time-points up to 6-months post-initiation of treatment, will be presented: opioid withdrawal, craving and satisfaction with treatment.
Findings and conclusions: To date, mean (SD) treatment satisfaction measured by the Treatment Satisfaction Questionnaire for Medication Global Satisfaction scores at 4, 12 and 24 weeks are 81.5 (17.9), 85.3 (17.8) and 87.5 (13.7). These data indicate that high levels of satisfaction with treatment can be achieved with iPRB in custodial settings. These findings are consistent with prior studies evaluating treatment satisfaction in community settings 1,2. 1. Frost M, et al. ‘Addiction ‘2019;114:1416 – 1426; 2. Lintzeris N, et al. ‘JAMA Network Open’ 2021;4(5): e219041.